Patent ID: 8603763
Filing Date: 2013-12-10
Classification: G01N

Abstract:
1. A method of determining the presence of a retinoblastoma protein (Rb)-mediated hematopoietic cancerous or pre-cancerous condition, said method comprising: providing a patient biopsy sample as a histologic section comprising fixed hematopoietic cells; exposing the patient sample to (i) a first antibody that recognizes phosphorylation of serine on the retinoblastoma protein (pS-Rb) and indicates that the cell bound by said first antibody has entered mid-G1 phase of cell cycle progression, and (ii) a second antibody that recognizes a cell surface or cytoplasmic marker for neoplastic hematopoietic cells; and identifying hematopoietic cells of the patient sample that are recognized by both the first and second antibodies, wherein recognition of hematopoietic cells of the patient biopsy sample by both first and second antibodies determines the presence of an Rb-mediated hematopoietic cancerous or pre-cancerous condition.